Abstract

Background and Objective: Breast cancer is one of the most common malignant tumours in women. In recent years, the incidence of this disease in China has been increasing significantly. This study aimed to preliminarily inquire into the expression and mechanism of LncRNA SNHG1 (SNHG1) in Breast Cancer (BC) to see if there is a treatment benefit. Materials and Methods: The expression of SNHG1 and its relationship with tumour diseases were preliminarily screened by ENCORI, an online biological information analysis website. Paired cancerous tissues and adjacent normal tissues were obtained from 50 BC patients who received treatment in the First Central Hospital of Baoding from December, 2017-June, 2018. The measurement of SNHG1 expression in BC tissues employed qRT-PCR. SNHG1 overexpression vector (sh-SNHG1 group) and inhibitory expression vector (si-SNHG1 group) were transfected into BC cells and a blank control group (NC group) was set up. The transfection efficiency was determined by qRT-PCR. Measurements of BC cell multiplication, apoptosis, migration and invasiveness as well as Caspase-3 and MMP-2 protein expression adopted MTT assay, flow cytometry, transwell and western blot, respectively. Results: In ENCORI database, SNHG1 was mostly up-regulated, moreover, the prognostic analysis revealed higher prognostic mortality in those with high SNHG1 levels. In this study, SNHG1 was significantly higher in cancerous tissues than in their noncancerous counterparts (p<0.05). In the si-SNHG1 group, cells showed reduced multiplication, viability and MMP-2 protein expression, while increased apoptosis and Caspase-3 protein expression (p<0.05). While the opposite results were observed in the sh-SNHG1 group (p<0.05). Conclusion: SNHG1 is upregulated in BC tissues. Downregulation of SNHG1 inhibits the malignant behaviours of BC cells and enhances apoptosis.